Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers. This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays. This integrated approach enhances our understanding of biomarkers by combining deep unbiased DIA-MS discovery proteomics with highly specific and ultra-sensitive mid- and high-plex NULISA assays for low-abundance proteins such as cytokines, chemokines and important disease protein biomarkers from plasma.
Biognosys Expands US Footprint with New Proteomics CRO Facility in Massachusetts
ZURICH--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, announced today the appointment of Beat Lüthi, Ph.D., as Board Director.
ZURICH--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services. The strategic partnership will encompass multiple strategic and commercial initiatives, including NeoGenomics labs offering access to Biognosys proteomics platforms, medical and scientific affairs-joint presentations and discussions, along with joint scientific and technical initiatives.
FORT MYERS, FL / ACCESSWIRE / April 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services announced a global strategic partnership agreement with Biognosys AG, a Switzerland-based leader in next-generation proteomics solutions for drug discovery and development this week. This partnership strengthens NeoGenomics' proteomics-based product capabilities for its Pharma Services Division from early discovery translational research through clinical trial work in oncology drug development programs.
ZURICH--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the details of its presence at the American Association for Cancer Research (AACR) Annual Meeting 2022, which will be held April 8-13, 2022, both in person in New Orleans, US and virtually. The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery™ and TrueTarget™. Additionally, Biognosys contributed to a poster that will be presented by its collaborator, NeoGenomics.
ZURICH--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
ZURICH--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today the launch of its expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with deep biological insights across the entire R&D pipeline, from early stage discovery to clinical settings.
ZURICH--(BUSINESS WIRE)--Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that it has obtained Good Laboratory Practice (GLP) certification from Swiss health authorities for preclinical studies. With this certification, Biognosys has become the first global proteomics service provider to be GLP certified, alongside being fully compliant with Good Clinical Practice (GCP).
ZURICH--(BUSINESS WIRE)--Biognosys, a leader in proteomics solutions for drug discovery and development, today announces the launch of its next-generation blood biomarker discovery solution, which will be offered as a contract research service. The service is designed to help researchers decipher the complexity of the blood proteome and unlock unbiased discoveries for pharma and diagnostics development and precision medicine.